Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation (Q28478937)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation	scientific article

Statements

scholarly article

0 references

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation (English)

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

object named as

Andrew L Kung

10

0 references

Paul G. Richardson

8

object named as

Paul G Richardson

0 references

Kenneth C. Anderson

9

object named as

Kenneth C Anderson

0 references

7

object named as

Nathanael S Gray

0 references

2

object named as

Jake Delmore

0 references

Constantine S Mitsiades

11

object named as

Constantine S Mitsiades

0 references

4

object named as

Melissa Ooi

0 references

Steffen Klippel

5

object named as

Steffen Klippel

0 references

author name string

Douglas W McMillin

1

0 references

Joseph Negri

3

0 references

Chandrasekhar V Miduturu

6

0 references

language of work or name

0 references

publication date

2011

0 references

0 references

6

0 references

7

0 references

e20226

0 references

copyright license

Creative Commons Attribution 4.0 International

7 July 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131271

19 March 2017

Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131271

29 September 2017

The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131271

29 September 2017

The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131271

29 September 2017

Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Res

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131271

29 September 2017

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131271

29 September 2017

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131271

29 September 2017

Overexpression of polo-like kinase 1 (PLK1) and chromosomal instability in bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131271

29 September 2017

The molecular classification of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131271

29 September 2017

Regulation of gene expression and cell division by Polo-like kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131271

29 September 2017

Normal cells, but not cancer cells, survive severe Plk1 depletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131271

29 September 2017

Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131271

29 September 2017

Tumor cell gene expression changes following short-term in vivo exposure to single agent chemotherapeutics are related to survival in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131271

2 June 2018

Targeting polo-like kinase 1 for cancer therapy.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020226

21 January 2018

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020226

21 January 2018

Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020226

21 January 2018

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020226

21 January 2018

An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020226

21 January 2018

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020226

21 January 2018

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020226

21 January 2018

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020226

21 January 2018

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du M

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0020226

21 January 2018

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3131271

27 November 2018

Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/21750699

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0020226

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

2011PLoSO...620226M

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28478937&oldid=1869153159"